MGX vs. MRNA, TVRD, IMRX, CTNM, ENGN, AMRN, TKNO, CAPR, REPL, and CGC
Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Tvardi Therapeutics (TVRD), Immuneering (IMRX), Contineum Therapeutics (CTNM), enGene (ENGN), Amarin (AMRN), Alpha Teknova (TKNO), Capricor Therapeutics (CAPR), Replimune Group (REPL), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry.
Metagenomi vs. Its Competitors
Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.
Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.
In the previous week, Moderna had 9 more articles in the media than Metagenomi. MarketBeat recorded 11 mentions for Moderna and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.76 beat Moderna's score of 0.56 indicating that Metagenomi is being referred to more favorably in the news media.
Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.
Moderna currently has a consensus target price of $41.81, suggesting a potential upside of 43.30%. Metagenomi has a consensus target price of $10.00, suggesting a potential upside of 215.26%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Moderna.
75.3% of Moderna shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 17.8% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Moderna has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
Summary
Moderna beats Metagenomi on 9 of the 16 factors compared between the two stocks.
Get Metagenomi News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Metagenomi Competitors List
Related Companies and Tools
This page (NASDAQ:MGX) was last updated on 10/8/2025 by MarketBeat.com Staff
